BRUCE A MOLITORIS, M.D.
Osteopathic Medicine at Walnut St, Indianapolis, IN
License number
Indiana 01041701
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
950 W Walnut St, Indianapolis, IN 46202
Phone
(317) 274-7453
Personal information
See more information about BRUCE A MOLITORIS at radaris.comName
Address
Phone
1213 Alderly Rd, Indianapolis, IN 46260
Carmel, IN
1213 Alderly Rd, Indianapolis, IN 46260
8039 Lutheran Lake, Nashville, IN 47448
8039 Lutheran Lake Rd, Seymour, IN 47274
Organization information
See more information about BRUCE A MOLITORIS at bizstanding.comBruce Molitoris MD
950 W Walnut St, Indianapolis, IN 46202
Industry:
Internist
Phone:
(317) 274-7453 (Phone)
Bruce Albert Molitoris
Indiana Institute Research Imaging - Bruce A Molitoris MD
950 W Walnut St, Indianapolis, IN 46202
Doing business as:
Indiana Institute Research Imaging - Timothy A Sutton MD
Phone:
(317) 274-2321 (Phone)
Categories:
Internal Medicine Physicians & Surgeons, Nephrology Physicians & Surgeons
Professional information
Bruce A Molitoris, Indianapolis IN
Specialties:
Nephrologist
Address:
950 W Walnut St, Indianapolis, IN 46202
Education:
Washington University, School of Medicine - Doctor of Medicine
University of Colorado Hospital-Anschutz Inpatient Pavilion - Fellowship - Nephrology (Internal Medicine)
University of Colorado Hospital-Anschutz Inpatient Pavilion - Residency - Internal Medicine
University of Colorado Hospital-Anschutz Inpatient Pavilion - Fellowship - Nephrology (Internal Medicine)
University of Colorado Hospital-Anschutz Inpatient Pavilion - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Nephrology (Internal Medicine)
Dr. Bruce A Molitoris - MD (Doctor of Medicine)
Hospitals:
950 W Walnut St SUITE 202, Indianapolis 46202
950 W Walnut St SUITE 202, Indianapolis 46202
950 W Walnut St SUITE 202, Indianapolis 46202
Education:
Medical Schools
Washington University St Louis
Graduated: 1979
Washington University St Louis
Graduated: 1979
Materials And Methods For Treating Diseases Caused By Genetic Disorders Using Aminoglycosides And Derivatives Thereof Which Exhibit Low Nephrotoxicity
US Patent:
2012015, Jun 21, 2012
Filed:
Dec 8, 2011
Appl. No.:
13/315190
Inventors:
Bruce A. Molitoris - Indianapolis IN, US
David M. Bedwell - Birmingham AL, US
Ruben M. Sandoval - Indianapolis IN, US
David M. Bedwell - Birmingham AL, US
Ruben M. Sandoval - Indianapolis IN, US
International Classification:
A61K 31/7036, C12N 5/02, A61P 3/00, A61P 21/00, A61P 11/00
US Classification:
514 40, 435375
Abstract:
Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener C2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of Becker's or Duchenne muscular dystrophy, Hurler's Syndrome and Cystic Fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health.
Materials And Methods For Treating Diseases Caused By Genetic Disorders Using Aminoglycosides And Derivatives Thereof Which Exhibit Low Nephrotoxicity
US Patent:
2010020, Aug 12, 2010
Filed:
May 28, 2009
Appl. No.:
12/473877
Inventors:
Bruce A. Molitoris - Indianapolis IN, US
David M. Bedwell - Birmingham AL, US
Ruben M. Sandoval - Indianapolis IN, US
David M. Bedwell - Birmingham AL, US
Ruben M. Sandoval - Indianapolis IN, US
International Classification:
A61K 31/7036, C07H 15/236, A61P 21/00
US Classification:
514 40, 536 136
Abstract:
Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener C2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of Becker's or Duchenne muscular dystrophy, Hurler's Syndrome and Cystic Fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health.
Renal Function Analysis Method And Apparatus
US Patent:
2013011, May 9, 2013
Filed:
Dec 13, 2012
Appl. No.:
13/713189
Inventors:
Daniel Meier - Indianapolis IN, US
Robert Bunch - Terre Haute IN, US
Bruce Molitoris - Indianapolis IN, US
Ruben Sandoval - Indianapolis IN, US
Matthew Rubin - Indianapolis IN, US
Robert Bunch - Terre Haute IN, US
Bruce Molitoris - Indianapolis IN, US
Ruben Sandoval - Indianapolis IN, US
Matthew Rubin - Indianapolis IN, US
Assignee:
PHARMACOPHOTONICS, INC. D/B/A FAST DIAGNOSTICS - Indianapolis IN
International Classification:
A61B 5/20, A61M 5/00, A61B 1/00, A61B 5/00
US Classification:
600317
Abstract:
A method for measuring a glomerular filtration rate in a mammalian kidney comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the blood stream of a mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent molecules is taken. A ratio is calculated to determine the health of the subject's kidney. This method measures volume of plasma distribution based on a fluorescence of a marker molecule relative to a fluorescence of a reporter molecule.
Renal Function Analysis Method And Apparatus
US Patent:
8591865, Nov 26, 2013
Filed:
Nov 15, 2010
Appl. No.:
12/946471
Inventors:
Exing Wang - Carmel IN, US
Daniel Meier - Indianapolis IN, US
Robert Bunch - Terre Haute IN, US
Bruce Molitoris - Indianapolis IN, US
Ruben Sandoval - Indianapolis IN, US
Matthew Rubin - Indianapolis IN, US
Erinn Sheridan - Indianapolis IN, US
Daniel Meier - Indianapolis IN, US
Robert Bunch - Terre Haute IN, US
Bruce Molitoris - Indianapolis IN, US
Ruben Sandoval - Indianapolis IN, US
Matthew Rubin - Indianapolis IN, US
Erinn Sheridan - Indianapolis IN, US
Assignee:
Pharmacophotonics, Inc. - Indianapolis IN
International Classification:
A61B 10/00, A61B 5/00, A61B 8/00
US Classification:
424 96, 424 111, 424 165, 424 91, 424 92
Abstract:
A method for measuring a glomerular filtration rate of a mammalian subject comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the vascular system of the mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent molecules is taken. A ratio is calculated to determine the glomerular filtration rate.
Measurement Of Body Fluid Volumes
US Patent:
2012027, Nov 1, 2012
Filed:
Apr 29, 2010
Appl. No.:
13/318097
Inventors:
Bruce A. Molitoris - Indianapolis IN, US
Exing Wang - San Antonio TX, US
Ruben M. Sandoval - Indianapolis IN, US
Exing Wang - San Antonio TX, US
Ruben M. Sandoval - Indianapolis IN, US
Assignee:
PHARMACOPHOTONICS, INC. - Indianapolis IN
International Classification:
A61K 49/00, A61B 5/145, A61B 5/1455, G01N 33/48, G06F 19/00
US Classification:
424 96, 73 6159, 600310, 702 25, 600309
Abstract:
The present invention is related generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interest include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and interstitial fluid volume (IFV). The methods are especially beneficial for subjects suffering from renal failure and particularly those undergoing renal dialysis. ECFV can be measured by administering a first molecule which is non-metabolized and permeable to vessel walls of the vascular system wherein the first molecule is distributed within the total vascular space as well as the interstitial space. TVPV can be measured by administering a second molecule which is non-metabolized and impermeable to vessel walls of the vascular system wherein the second molecule is distributed within only the vascular space. IFV can then be calculated using the equation IFV=ECFV−TVPV.
Method And Apparatus For Kidney Function Analysis
US Patent:
2013010, Apr 25, 2013
Filed:
Dec 10, 2012
Appl. No.:
13/709242
Inventors:
Indiana University Research and Technology Corpr - Indianapolis IN, US
Bruce A. MOLITORIS - Indianapolis IN, US
Ruben M. SANDOVAL - Indianapolis IN, US
Bruce A. MOLITORIS - Indianapolis IN, US
Ruben M. SANDOVAL - Indianapolis IN, US
Assignee:
Indiana University Research and Technology Corporation - Indianapolis IN
International Classification:
A61K 49/00
US Classification:
424 96, 424 91
Abstract:
A method and apparatus for determining physiological data related to an animal, such as kidney diagnostics data, is provided. The method includes injecting a mixture of a first and a second molecule into an animal (e.g., a human patient), determining a molecular ratio of the molecules, and determining the physiological data based on the molecular ratio. The apparatus includes a number of finger receiving apertures, a light generation circuit, a light detection circuit, a pulse counting circuit, and a user interface.
Method And Apparatus For Kidney Function Analysis
US Patent:
8329143, Dec 11, 2012
Filed:
Apr 18, 2006
Appl. No.:
11/911895
Inventors:
Weiming Yu - Indianapolis IN, US
Bruce A. Molitoris - Indianapolis IN, US
Bruce A. Molitoris - Indianapolis IN, US
Assignee:
Indiana University Research and Technology Corporation - Indianapolis IN
International Classification:
A61K 49/00, G01N 31/00
US Classification:
424 91, 424 111, 424 96
Abstract:
A method and apparatus for determining physiological data related to an animal, such as kidney diagnostics data, is provided. The method includes injecting a mixture of a first and a second molecule into an animal (e. g. , a human patient), determining a molecular ratio of the molecules, and determining the physiological data based on the molecular ratio. The apparatus includes a number of finger receiving apertures, a light generation circuit, a light detection circuit, a pulse counting circuit, and a user interface.
Treating Acute Renal Failure With Soluble Thrombomodulin Variants
US Patent:
2010008, Apr 8, 2010
Filed:
Dec 10, 2007
Appl. No.:
12/514812
Inventors:
Brian William Grinnell - Indianapolis IN, US
Bryan Edward Jones - Carmel IN, US
Bruce A. Molitoris - Indianapolis IN, US
Bryan Edward Jones - Carmel IN, US
Bruce A. Molitoris - Indianapolis IN, US
Assignee:
ELI LILLY AND COMPANY - Indianapolis IN
International Classification:
A61K 38/17, C07K 16/00
US Classification:
514 12, 530381
Abstract:
The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction with standard of care, soluble thrombomodulin that does not activate Protein C will prevent or reduce acute kidney injury and subsequent morbidity and mortality.